ArticleHealth science reports2026
Patient-Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross-Sectional Survey.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Attention and Suggestions on the Study of Symptom Clusters in ICI Treatment.Health science reports · 2026Article
- Patient-Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross-Sectional Survey.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Cancer treatment management necessitates comprehensive symptom burden assessment, particularly with therapies like immune checkpoint inhibitors (ICIs), known for unique toxicities. While ICIs show promising outcomes, they also induce immune-related adverse events (irAEs), posing challenges due to their varied onset, duration, and severity. Traditional clinician-reported tools may overlook nuances, hence the importance of Patient-Reported Outcomes (PRO). Symptom clusters, representing interrelated symptoms sharing biological mechanisms, offer a holistic approach to symptom management yet are understudied in ICI therapy. Methods: A cross-sectional survey at Guang'anmen Hospital, China, from January 2021 to March 2023, enrolled cancer patients undergoing ICI therapy. Validated PRO tools captured symptoms, interference, and quality of life. Descriptive statistics summarized demographics, while exploratory factor analysis identified symptom clusters. Multiple linear regression analyzed factors influencing symptom burden, and Pearson correlation examined relationships. Results: Among 213 participants, predominantly male (72%) with lung cancer (75%), most had Stage IV disease (59%). Fatigue (79.8%) and dry mouth (69.5%) were prevalent, with fatigue being the highest incidence of moderate to severe cases. Five symptom clusters were identified: emotion-function, respiratory, autonomic nerve dysfunction, mucosa-related, and skin-related. Poor Eastern Cooperative Oncology Group performance status and time from the first immunotherapy ≤ 3 months correlated with higher symptom burden. Participants reported overall good health-related quality of life, with a median score of 7 (IQR 5-8). The severity of symptom burden correlates with poorer quality of life. Conclusion: During ICI treatment, cancer patients endure multi-faceted symptoms, forming clusters that may have distinct biological underpinnings. Early recognition and mechanism-driven management of these clusters are crucial for mitigating treatment toxicities and improving patient outcomes. Further research is warranted to deepen our understanding and refine symptom management strategies. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.